Hannah Slevin

Hannah Slevin

Auto-generated profile, based on publicly available information

Hannah Slevin

National Institute for Health and Care Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust and University of Manchester, Manchester, UK

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2026 in European Journal of Human Genetics
Verified
Journal Article
Open access
Thomas Edward Barry WrightThomas Edward Barry Wright
Thomas Edward Barry Wright
HSHannah Slevin
Hannah Slevin
SMSinéad Magnier
Sinéad Magnier
MCMatthew Carr
Matthew Carr
SGShruti Garg
Shruti Garg
SBSiddharth Banka
Siddharth Banka
Rare disease studies often rely on small, selected cohorts, are resource-intensive and difficult to scale. UK primary care electronic health record (EHR) databases provide population-based, longitudinal data, but their use for rare genetic disease research has not been systematically examined. Through systematic mapping of publications from five UK primary care EHR databases (CPRD, OPCRD, QResearch, SAIL Databank and THIN), we found that only 0.82% (47 of 5754) of studies reported on rare genetic diseases. Of these, 77% (36 of 47) linked to external datasets. Study designs included case-control, cross-sectional and cohort studies. Cohort designs predominated, often with individual-level matched comparators. Case ascertainment was primarily based on routinely recorded diagnostic codes. Most studies examined a single disease, collectively encompassing 23 conditions. There was a skew towards multisystem, neurological, autosomal dominant and single-gene disorders, with relatively higher population frequencies and therapeutic tractability. Rare disease sample sizes ranged from 21 to 5059 (median 392). Important insights were revealed into phenotypic variation, phenotype expansion, complications and management outcomes, including findings not readily identifiable in traditional studies. Examples include higher prevalence of hereditary haemorrhagic telangiectasia in females, consistent with sex-modified phenotypic expression; non-skeletal complications and premature mortality in X-linked hypophosphataemia; and elevated malignancy risk in myotonic dystrophy type 1 with type 2 diabetes, potentially attenuated by metformin. In conclusion, UK primary care EHR databases are markedly underutilised for rare genetic diseases. For many conditions, limited availability of diagnostic codes is a constraint. However, their demonstrated capacity, scale, scope and population representativeness support wider use.

20 January 2026 in BJPsych Advances
Verified
Journal Article
Open access
PDF file
SGSarah Golding
Sarah Golding
HSHannah Slevin
Hannah Slevin
AMAmy Sarah McCulloch
Amy Sarah McCulloch
EBEmily Birch
Emily Birch
ANAna Nikiforovski
Ana Nikiforovski
RERachel Elvins
Rachel Elvins
SUMMARY: Avoidant/restrictive food intake disorder (ARFID) is a condition characterised by an avoidance or restriction of food intake that has a detrimental impact on physical health, psychosocial functioning or both. ARFID has now been classified in ICD-11, alongside DSM-5; however, challenges remain for healthcare professionals in recognising ARFID in young people and identifying best practice for managing their care. This educational article aims to provide an update on the epidemiology and clinical presentation of ARFID in children and young people, with a particular focus on co-occurring neurodevelopmental conditions and psychiatric disorders. A multidisciplinary approach to assessment and management is key, working closely with the young person and the system around them. Physical and psychosocial risk assessment has been aided by the publication of the medical emergencies in eating disorders (MEED) guidelines. Crucially, there is a need for further research into ARFID in order to develop evidence-based standardised guidelines for assessment, management and transition to adult services if required.

9 May 2026 in EJC Paediatric Oncology
Verified
Journal Article
Open access
HSHannah Slevin
Hannah Slevin
FAFatmaelzahraa Awadalla
Fatmaelzahraa Awadalla
RFRichard G. Feltbower
Richard G. Feltbower
LRLouise Robinson
Louise Robinson
JKJohn-Paul Kilday
John-Paul Kilday
MMMartin McCabe
Martin McCabe

5 December 2023 in medRxiv
Verified
Preprint
Open access
PDF file
HSHannah Slevin
Hannah Slevin
FKFiona Kehinde
Fiona Kehinde
JBJannath Begum-Ali
Jannath Begum-Ali
CECeri Ellis
Ceri Ellis
EBEmma Burkitt-Wright
Emma Burkitt-Wright
TTthe EDEN-STAARS team
the EDEN-STAARS team
Objective This prospective cohort study examines the cognitive, behavioural, ADHD trait and autism symptom development in infant and pre-school children with Neurofibromatosis 1 (NF1) compared with typically developing (TD) children without a family history of neurodevelopmental conditions. Methods Data from standardised tests was gathered at 5, 10, 14, 24 and 36 months of age (NF1 n=35, TD n=29). Developmental trajectories of cognitive and adaptive behavioural development from 5 to 36 months were analysed using linear mixed modelling. Measures of ADHD and autism traits were assessed at 24 and 36 months. Results The developmental trajectory of cognitive skills (all domains of the Mullen Scales of Early Learning -MSEL) and behavioural skills (four domains of the Vineland Adaptive Behaviour Scale -VABS) differed significantly between NF1 and TD groups. Post-hoc tests demonstrated that the NF1 participants scored significantly lower than TD participants at 24 months on all MSEL and VABS domains. The NF1 cohort demonstrated higher mean autism and ADHD traits at 24 months and 14% of the NF1 cohort met a research diagnostic classification for autism at 36 months. Conclusion By 24 months of age, the NF1 cohort show lower cognitive skills and adaptive behaviour and higher levels of autism and ADHD traits as compared to TD children.